Literature DB >> 11418691

Stem cell factor-induced leukotriene B4 production cooperates with eotaxin to mediate the recruitment of eosinophils during allergic pleurisy in mice.

A Klein1, A Talvani, P M Silva, M A Martins, T N Wells, A Proudfoot, N W Luckacs, M M Teixeira.   

Abstract

The understanding of the mechanisms underlying eosinophil recruitment in vivo may aid in the development of novel strategies for the treatment of allergic disorders. In this study, we investigated the role of chemokines in the cascade of events leading to eosinophil recruitment in a stem cell factor (SCF)- and leukotriene B(4) (LTB(4))-dependent allergic pleurisy model in mice. The intrapleural administration of the eosinophil-active chemokines eotaxin, RANTES, and macrophage-inflammatory protein 1alpha (MIP-1alpha) induced a time- and dose-dependent eosinophil recruitment. Pretreatment with anti-eotaxin, but not anti-RANTES or anti-MIP-1alpha, blocked the recruitment of eosinophils following Ag challenge of sensitized animals, and significant eotaxin immunoreactivity was detected in the pleural cavity of these animals. Similarly, only the anti-eotaxin inhibited the eosinophil recruitment induced by injection of SCF in naive animals. However, blockade of SCF did not inhibit the release of eotaxin after Ag challenge of sensitized mice. Akin to its effects on SCF and in the allergic reaction, eotaxin-induced eosinophil recruitment was blocked by the LTB(4) receptor antagonist CP105696. Nevertheless, SCF, but not eotaxin, appeared to regulate the endogenous release of LTB(4) after Ag challenge. Finally, we show that low doses of eotaxin synergized with LTB(4) to induce eosinophil recruitment in the pleural cavity. Overall, the present results show that eotaxin and SCF-induced LTB(4) cooperate to induce eosinophil recruitment into sites of allergic inflammation. Cooperation between inflammatory mediators must be an important phenomenon in vivo, explaining both the ability of lower concentrations of mediators to induce a full-blown functional response and the effectiveness of different strategies at inhibiting these responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418691     DOI: 10.4049/jimmunol.167.1.524

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Chemical composition and anti-inflammatory activity of the leaves of Byrsonima verbascifolia.

Authors:  Aline Aparecida Saldanha; Lucas Fernandes do Carmo; Sara Batista do Nascimento; Natália Alves de Matos; Clarice de Carvalho Veloso; Ana Hortência Fonsêca Castro; Ric C H De Vos; André Klein; João Máximo de Siqueira; Carlos Alexandre Carollo; Thalita Vieira do Nascimento; Mônica Cristina Toffoli-Kadri; Adriana Cristina Soares
Journal:  J Nat Med       Date:  2016-06-08       Impact factor: 2.343

2.  Anti-inflammatory and antinociceptive properties of the hydroalcoholic fractions from the leaves of Annona crassiflora Mart. in mice.

Authors:  Cristina da Costa Oliveira; Natália Alves de Matos; Clarice de Carvalho Veloso; Gisele Avelar Lage; Lúcia Pinheiro Santos Pimenta; Igor Dimitri Gama Duarte; Thiago Roberto Lima Romero; André Klein; Andrea de Castro Perez
Journal:  Inflammopharmacology       Date:  2018-01-25       Impact factor: 4.473

3.  Mast cell tryptase induces eosinophil recruitment in the pleural cavity of mice via proteinase-activated receptor 2.

Authors:  Natália A Matos; Josiane F Silva; Tamires C Matsui; Karine A Damasceno; Igor D G Duarte; Virginia S Lemos; Geovanni D Cassali; André Klein
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

4.  Defective eosinophil hematopoiesis ex vivo in inbred Rocky Mountain White (IRW) mice.

Authors:  Kimberly D Dyer; Katia E Garcia-Crespo; Caroline M Percopo; Aaron B Bowen; Tomonobu Ito; Karin E Peterson; Alasdair M Gilfillan; Helene F Rosenberg
Journal:  J Leukoc Biol       Date:  2011-08-30       Impact factor: 4.962

5.  Platelet-activating factor drives eotaxin production in an allergic pleurisy in mice.

Authors:  André Klein; Vanessa Pinho; Ana Letícia Alessandrini; Takao Shimizu; Satoshi Ishii; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

6.  Niacin inhibits carrageenan-induced neutrophil migration in mice.

Authors:  Raphael Gomes Ferreira; Tamires Cardoso Matsui; Lindisley Ferreira Gomides; Adriana Martins Godin; Gustavo Batista Menezes; Márcio de Matos Coelho; André Klein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-03-26       Impact factor: 3.000

7.  Leukotriene B4 mediates gammadelta T lymphocyte migration in response to diverse stimuli.

Authors:  Maria Fernanda de Souza Costa; Raquel de Souza-Martins; Mariana C de Souza; Cláudia F Benjamim; Bruno Piva; Bruno L Diaz; Marc Peters-Golden; Maria das Graças Henriques; Cláudio Canetti; Carmen Penido
Journal:  J Leukoc Biol       Date:  2009-10-30       Impact factor: 4.962

8.  Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis.

Authors:  Angélica T Vieira; Caio T Fagundes; Ana Leticia Alessandri; Marina G M Castor; Rodrigo Guabiraba; Valdinéria O Borges; Kátia Daniella Silveira; Erica L M Vieira; Juliana L Gonçalves; Tarcilia A Silva; Maud Deruaz; Amanda E I Proudfoot; Lirlândia P Sousa; Mauro M Teixeira
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

9.  Protease-activated receptor 4 plays a role in lipopolysaccharide-induced inflammatory mechanisms in murine macrophages.

Authors:  A Barra; K M Freitas; D G Marconato; P Faria-Pinto; M T P Lopes; André Klein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-11-07       Impact factor: 3.000

10.  Mechanisms underlying the inhibitory effects of tachykinin receptor antagonists on eosinophil recruitment in an allergic pleurisy model in mice.

Authors:  Ana Leticia Alessandri; Vanessa Pinho; Danielle G Souza; Maria Salete de A Castro; Andre Klein; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2003-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.